New Research Released on Celsion Corporation (CLSN-NASDAQ)

Posted by Karen Goldfarb

December 9, 2020 at 3:35 PM

An Executive Informational Overview (EIO) is now available on Celsion Corporation, a fully integrated biopharmaceutical company focused on developing cancer therapies for difficult-to-treat forms of cancers. The 68-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Download Celsion Corporation  Initiation Report

Read More

Topics: biotech, immunotherapy, cancer, autoimmune, hepatocellular cancer, GEN-1, ovarian cancer, interleukin-12, IL-12, ThermoDox, primary liver cancer, celsion

New Research Released on CEL-SCI Corporation (CVM-NYSE)

Posted by Karen Goldfarb

June 3, 2020 at 12:34 PM

An Executive Informational Overview (EIO) is now available on CEL-SCI Corporation, a clinical-stage biotechnology company developing immunotherapy technologies to treat cancer, autoimmune, and infectious diseases. The 86-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Download CEL-SCI Corporation Report

Read More

Topics: biotech, immunotherapy, CEL-SCI, infectious diseases, leaps, cancer, autoimmune, head and neck cancer, squamous cell carcinoma, rheumatoid arthritis, covid19, cervical dysplasia

Making the Most of Your Investor Presentation

Posted by Laura Swartz

January 12, 2016 at 7:52 PM


“Building a profile and becoming ‘known’ is a critical part of raising money…” — Erin Righetti, partnering360®

Healthcare conferences are in full swing this week in San Francisco, with attendees from companies large and small making the circuit at J.P. Morgan’s Annual Healthcare Conference, the EBD Group’s annual Biotech Showcase™, the StartUp Health Festival, and many others. From corporate presentations to strategic one-on-one meetings and even impromptu run-ins, networking opportunities abound and it is important for CEOs to be able to quickly, concisely, and effectively pitch their company to potential investors and/or partners.

Read More

Topics: Crystal Research Associates, biotech

FULL VIDEO (Reuters TV): Biotech Stocks To Watch and More

Posted by Colleen Koski

August 15, 2013 at 1:25 PM

Last week, Jeff Kraws sat down with Rhonda Schaffler at Reuters to discuss opportunities and trends in the biotech space. Mr. Kraws is a veteran Wall Street sell-side analyst with more than 20 years of experience and is also cofounder and CEO of Crystal Research Associates. If you enjoyed the short clip of this interview released earlier this week, the full segment (available below) goes into more detail on individual biotech stocks and the events every investor should be watching out for.

Read More

Topics: AtheroNova, Crystal Research Associates, Unilife Corp., biotech, MetaStat, Reuters

Jeff Kraws Talks Opportunities for Biotech Investors

Posted by Laura Swartz

August 13, 2013 at 11:47 AM

Biotechnology--the use of living organisms or other biological systems in the manufacture of drugs or other products--has emerged as a critical sector for healthcare investors over the past several years. In 2012 alone, the biotech sector grew over 40% according to S&P Capital IQ. Biotech is expected to remain a hot market going forward, with considerable room for more growth. Last week, biotech firm Intrexon Corp. (XON-NYSE) made its IPO debut at $16/share and immediately soared 38%. Nearly double its IPO price, Intrexon opened at $29.99 this morning, August 13th. 

Read More

Topics: Crystal Research Associates, Newsworthy Events, biotech

AtheroNova Completes $2.9 Million Private Placement of Common Stock

Posted by Laura Swartz

October 11, 2012 at 10:30 AM

Biotech company AtheroNova Inc. (AHRO-OTC) this morning announced that it raised over $2.9 million in gross proceeds from a sale of its Common Stock. This funding represents a major milestone for the company, as it is expected to support both Phase I and Phase II clinical trials for AtheroNova's anti-atherosclerotic plaque compounds in development. AtheroNova's most advanced product candidate, AHRO-001, works to significantly reduce the incidence and severity of plaque deposits, which are known to be the main underlying cause of cardiovascular disease, including heart attack, stroke, and peripheral artery disease (PAD).

Read More

Topics: AtheroNova, biotech

Top Nanotech Innovators of 2012

Posted by Laura Swartz

September 13, 2012 at 12:59 PM

Last week in Boston, the NanoBusiness Commercialization Association (NanoBCA), a national nonprofit trade association for nanotechnology-enabled business, held a NanoBusiness conference where the association announced the "Top Nanotech Innovators of 2012," highlighting companies that create novel and potentially disruptive technologies in the nanotech sector. NanoBCA recognized 20 large corporations as well as 20 emerging enterprises. The Figure below highlights NanoBCA's view of the top nanotechnology innovators for 2012 and specifies the area(s) for which the company was recognized.    

Read More

Topics: nanotechnology, biotech

NEW RESEARCH: AtheroNova (AHRO-OTC) Works to Unclog Your Arteries

Posted by Laura Swartz

June 6, 2012 at 10:25 AM

New research available in our library at gives readers a complete description of the business of AtheroNova: its product development, milestones, competitive pressures, market opportunities, risks, and more. A 52-page report is available here, with future Quarterly Updates coming as AtheroNova advances this year.

Read More

Topics: AtheroNova, New Research, biotech

TapImmune's New State-of-the-Art Lab Facilities and Office Space

Posted by Karen Goldfarb

January 23, 2012 at 11:19 AM

We recently received an update from TapImmune Inc. (TPIV-OTC.BB) regarding the Company's newly acquired laboratory and office space in South Lake Union (Seattle's up-and-coming biotech hub). Through a strategic sublease with the Puget Sound Blood Center Research Institute, TapImmune's scientific research team now has access to shared equipment and state-of-the-art core laboratories for DNA sequencing, Mass Spectrometry (shown below), and Fluorescent Activated Cell Sorting (FACS)—a unique opportunity for any startup company.

Read More

Topics: biotech, TapImmune, cancer vaccine, immunotherapy, Mark Reddish, Puget Sound Blood Center

Healthcare Conferences and News: Week of 1/9 to 1/13

Posted by Karen Goldfarb

January 13, 2012 at 11:20 AM

This has been a big week for healthcare and biotech.

Read More

Topics: Crystal Research Associates, NVIV, GenSpera, OneMedForum, MedPro, biotech, Advaxis, Peregrine, Neuralstem, Leslie Ziegler, Gunnar Weikert, PPHM, General Cannabis, SearchCore

Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Date

see all

Posts by Topic